Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
2061-2080 of 2,120 trials

Head and Neck Cancer: New Treatment Approach with Pembrolizumab

We are studying a new sequence of treatments for patients with recurrent head and neck cancer to see if it improves survival compared to standard therapies. We will also evaluate how well patients tolerate the treatments and their quality of life.

Recurrent Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Recovery After Gallbladder Surgery: Esmolol vs. Sufentanil

We are comparing two medications to see which one helps patients recover more comfortably after laparoscopic gallbladder surgery. This study aims to improve patient comfort during the recovery process.

Laparoscopic Gallbladder Removal1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOrthopedics and TraumatologyOtolaryngology

Metastatic Colorectal Cancer: RAXO Trial

We are studying how metastatic colorectal cancer behaves and the effectiveness of different treatments in patients. This research aims to improve surgical options and overall patient outcomes.

Advanced Colorectal Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Type 2 Diabetes: LY3457263 Treatment Study

We are testing a new medication, LY3457263, in people with type 2 diabetes who are not meeting their blood sugar goals on current treatments. The study will compare its effects to a placebo over 24 weeks.

Type 2 DiabetesEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Influenza Vaccine Study: OVX836

We are testing the OVX836 influenza vaccine in healthy adults to see if it can prevent influenza compared to a placebo. This study will also look at the vaccine's safety and how well it triggers an immune response.

Influenza6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteInfectious Diseases

Generalized Myasthenia Gravis: Descartes-08 Treatment

We are studying a new treatment called Descartes-08 for people with generalized myasthenia gravis. The trial aims to see if it helps improve daily activities and muscle strength compared to a placebo.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Immune Thrombocytopenia: NVG-2089 Treatment Study

We are testing a new intravenous treatment, NVG-2089, for individuals with Immune Thrombocytopenia. The study aims to evaluate its safety and how well it works in increasing platelet counts.

Immune Thrombocytopenia (ITP)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematology

Head and Neck Cancer: NBTXR3 Treatment Study

We are studying a new treatment involving NBTXR3 with or without cetuximab for elderly patients with locally advanced head and neck cancer. The goal is to see if this approach improves survival compared to standard radiotherapy.

Head and Neck Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cemiplimab for Advanced Adrenocortical Cancer

We are studying whether cemiplimab can help patients with advanced adrenocortical cancer maintain their health after initial treatment. This trial focuses on those who have not experienced disease progression.

Adrenocortical Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Health: Orticumab for Inflammation After Heart Attack

We are studying whether orticumab can reduce inflammation in people who have had a heart attack and show elevated coronary inflammation. The trial will also evaluate the safety of this treatment.

Heart Attack6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Chronic Obstructive Pulmonary Disease: Verekitug Study

We are investigating whether Verekitug can help people with moderate-to-severe COPD manage their symptoms and improve lung function. The study will also assess the safety and overall impact on quality of life.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Platysma Prominence: NT 201 Treatment Study

We are investigating whether NT 201 can safely reduce moderate to severe platysma prominence in adults compared to a placebo. This study aims to find out if this treatment can improve appearance and confidence.

Moderate to Severe Platysma Prominence3-6 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesDermatology

Kidney Transplant: Reduced Immunosuppression for Older Adults

We are studying whether a lower dose of immunosuppressive medication is as effective and safe as the standard dose for older adults after kidney transplantation. This may help improve their overall health and quality of life.

End-stage Renal Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Hidradenitis Suppurativa: Sonelokimab Study

We are studying the long-term safety and effectiveness of sonelokimab for people with moderate to severe hidradenitis suppurativa. This research aims to improve symptoms and quality of life for participants.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Advanced Breast Cancer: PF-07248144 with Fulvestrant

We are studying a new treatment combining PF-07248144 and fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer. This trial aims to see if it helps patients whose cancer has progressed after prior therapy.

Hormone Receptor-Positive, HER2-Negative Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Breast Cancer: Patritumab Deruxtecan vs. Standard Treatment

We are studying a new medication for patients with hormone receptor-positive, HER2-negative advanced breast cancer. The goal is to see if it works better than the current treatment options.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)3-6 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

Dengue Vaccine Qdenga: Antibody Response Study

We are examining how the Qdenga vaccine affects antibody levels for other flavivirus infections in Swedish travelers. This study aims to see if vaccination leads to higher antibody levels that could interfere with diagnostic tests.

Healthy Participants3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesAllergologyHematologyInfectious Diseases

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Nasopharyngeal Carcinoma: Imaging Study with [68Ga]Ga-DOTA-TOC

We are exploring a new imaging method to assess tumors in patients with EBV-related nasopharyngeal carcinoma. This study aims to improve treatment choices by understanding how the tumor responds to therapy.

Nasopharyngeal Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology